| 000 | 01725 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250515014316.0 | ||
| 264 | 0 | _c20060720 | |
| 008 | 200607s 0 0 eng d | ||
| 022 | _a1079-0713 | ||
| 024 | 7 |
_a10.1097/00044067-200601000-00007 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGearhart, Michelle M | |
| 245 | 0 | 0 |
_aHyperglycemia in the critically ill patient. _h[electronic resource] |
| 260 |
_bAACN clinical issues _c |
||
| 300 |
_a50-5 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aBlood Glucose _xmetabolism |
| 650 | 0 | 4 | _aClinical Protocols |
| 650 | 0 | 4 |
_aCritical Care _xmethods |
| 650 | 0 | 4 |
_aCritical Illness _xepidemiology |
| 650 | 0 | 4 |
_aEpinephrine _xphysiology |
| 650 | 0 | 4 | _aEvidence-Based Medicine |
| 650 | 0 | 4 |
_aGlucagon _xphysiology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydrocortisone _xphysiology |
| 650 | 0 | 4 |
_aHyperglycemia _xdiagnosis |
| 650 | 0 | 4 |
_aHypoglycemic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aHypothalamo-Hypophyseal System _xphysiopathology |
| 650 | 0 | 4 |
_aInsulin _xtherapeutic use |
| 650 | 0 | 4 |
_aInsulin Resistance _xphysiology |
| 650 | 0 | 4 | _aMorbidity |
| 650 | 0 | 4 |
_aNorepinephrine _xphysiology |
| 650 | 0 | 4 |
_aPituitary-Adrenal System _xphysiopathology |
| 650 | 0 | 4 | _aPractice Guidelines as Topic |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aSepsis _xetiology |
| 650 | 0 | 4 |
_aStress, Physiological _xcomplications |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xphysiology |
| 700 | 1 | _aParbhoo, Shilpa K | |
| 773 | 0 |
_tAACN clinical issues _gvol. 17 _gno. 1 _gp. 50-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/00044067-200601000-00007 _zAvailable from publisher's website |
| 999 |
_c16075481 _d16075481 |
||